AzTrials
AzTrials

Mucous Membrane PemphigoidPhase 2NCT05263505

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

A Phase 2 study testing Baricitinib 2 MG [Olumiant], Methotrexate and Azathioprine in people with Mucous Membrane Pemphigoid and Cicatrizing Conjunctivitis, run by Washington University School of Medicine at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Baricitinib 2 MG [Olumiant], Methotrexate and Azathioprine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteUnited States
Study dates
21 Feb 2022to 11 Sep 2023
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients are eligible to be included in the study only if they meet all the following criteria:
  • Type of Patient and Disease Characteristics
  • Are at least 18 years of age
  • Have a clinical diagnosis of Ocular Mucous Membrane Pemphigoid
  • The treating ophthalmologist will have excluded alternative etiologies that can cause cicatrizing conjunctivitis such as:
  • Rosacea
Show all 38Show fewer
  • Atopic dermatitis
  • Lichen Planus
  • Iatrogenic interventions, e.g. glaucoma eye drops
  • Stevens-Johnsons Syndrome
  • Graft vs Host Disease
  • Have active disease based on ophthalmologic exam
  • Patient Characteristics
  • Nonpregnant, nonbreastfeeding female or male patient
  • Female patients of child-bearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with the opposite sex.
  • Total abstinence is defined as refraining from intercourse during the entirety of the study and for at least 1 week following the last dose of investigational product. Periodic abstinence such as calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception.
  • Otherwise, female patients of childbearing potential must agree to use 2 effective methods of contraception, where at least 1 form is highly effective, for the entirety of the study and for at least 1 week following the last dose of investigational product.
  • The following contraception methods are considered acceptable (the patient should choose 2, and 1 must be highly effective [defined as less than 1% failure rate per year when used consistently and correctly]):
  • Highly effective birth control methods:
  • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
  • Progestogen- only containing hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
  • intrauterine device (IUD)/intrauterine hormone-releasing system (IUS)
  • vasectomized male (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
  • Effective birth control methods:
  • o Male or female condom with spermicide. It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.
  • Diaphragm with spermicide
  • Cervical sponge
  • Cervical cap with spermicide Note: When local guidelines concerning highly effective or effective methods of birth control differ from the above, the local guidelines must be followed.
  • Female patients of non-child-bearing potential are not required to use birth control and they are defined as:
  • Women who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation)
  • Post-menopausal - defined either as
  • o A woman at least 50 years of age with an intact uterus, not on hormone therapy, who has either
  • Cessation of menses for at least 1 year
  • At least 6 months of spontaneous menorrhea with follicle-stimulating hormone >40 mIU/mL
  • Women aged 55 years or older who are not on hormone therapy, and who have had at least 6 months of spontaneous amenorrhea
  • Women aged 55 years or older who have a diagnosis of menopause
  • Informed Consent
  • Must read and understand the informed consent approved by the institutional review board (IRB)/ethics review board (ERB) governing the site and provide written informed consent.

Who cannot join

  • Patients will be excluded from study enrollment if they meet any of the following criteria:
  • Disease Characteristics
  • Have rapidly progressive disease, as determined by the treating ophthalmologist, that places the patient at an unacceptable risk for participating in the study
  • Medical Conditions
  • Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study that, in the opinion of the investigator would pose an unacceptable risk to the patient.
  • Have experienced any of the following within 12 weeks of screening: VTE (DVT/pulmonary embolism [PE]), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
Show all 62Show fewer
  • Have a history of recurrent (≥ 2) VTE (DVT/PE).
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.
  • Have a history of lymphoproliferative disease; have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years prior to randomization.
  • The following may be exempted:
  • Patients with cervical carcinoma in situ that has been resected with no evidence of recurrence or metastatic disease for at least 3 years may participate in the study.
  • Patients with basal cell or squamous epithelial skin cancers that have been completely resected with no evidence of recurrence for at least 3 years may participate in the study.
  • Have a current or recent (<4 weeks prior to randomization) clinically serious viral, bacterial, fungal, or parasitic infection or any other active or recent infection that in the opinion of the investigator, would pose an unacceptable risk to the patient if participating in the study.
  • Note: For example, a recent viral upper respiratory tract infection or uncomplicated urinary tract infection need not be considered clinically serious.
  • Have symptomatic herpes simplex at the time of randomization
  • Have had symptomatic herpes zoster infection within 12 weeks prior to randomization
  • Have a history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement).
  • Have a positive test for hepatitis B virus (HBV) defined as:
  • positive for hepatitis B surface antigen (HBsAg), or
  • positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA)
  • Note: Patients who are HBcAb-positive and HBV DNA-negative may be enrolled in the study but will require additional HBV DNA monitoring during the study.
  • Have hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic acid [RNA]-positive).
  • Note: Patients who have documented anti-HCV treatment for a past HCV infection AND are HCV RNA-negative may be enrolled in the study.
  • Have evidence of HIV infection and/or positive HIV antibodies
  • Have had household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB
  • Have evidence of active TB or latent TB
  • Have evidence of active TB, defined in this study as the following:
  • Positive purified protein derivative (PPD) test (≥5 mm induration between approximately 2 and 3 days after application, regardless of vaccination history), medical history, clinical features, and abnormal chest x-ray at screening
  • QuantiFERON®-TB Gold test or T-SPOT®.TB test (as available and if compliant with local TB guidelines) may be used instead of the PPD test. Patients are excluded from the study if the test is not negative and there is clinical evidence of active TB
  • Exception: patients with a history of active TB who have documented evidence of appropriate treatment, have no history of re-exposure since their treatment was completed, have no clinical features of active TB, and have a screening chest x-ray with no evidence of active TB may be enrolled if other entry criteria met. Such patients would not be required to undergo the protocol-specific TB testing for PPD, QuantiFERON®-TB Gold test, or T-SPOT®.TB test but must have a chest x-ray at screening (i.e., chest imaging performed within the past 6 months will not be accepted).
  • Have evidence of untreated/inadequately or inappropriately treated latent TB, defined in this study as the following:
  • Positive PPD test, no clinical features consistent with active TB, and a chest x-ray with no evidence of active TB at screening; or
  • If the PPD test is positive and the patient has no medical history or chest x-ray findings consistent with active TB, the patient may have a QuantiFERON®-TB Gold test or T-SPOT®.TB test (as available and if compliant with local TB guidelines). If the test results are not negative, the patient will be considered to have latent TB (for purposes of this study); or
  • QuantiFERON®-TB Gold test or T- SPOT®.TB test (as available and if compliant with local TB guidelines) may be used instead of the PPD test. If the test results are positive, the patient will be considered to have latent TB. If the test is not negative, the test may be repeated once within approximately 2 weeks of the initial value. If the repeat test results are again not negative, the patient will be considered to have latent TB (for purposes of this study).
  • Exception: Patients who have evidence of latent TB may be enrolled if he or she completes at least 4 weeks of appropriate treatment prior to randomization and agrees to complete the remainder of treatment while in the trial.
  • Exception: Patients with a history of latent TB who have documented evidence of appropriate treatment, have no history of re-exposure since their treatment was completed, have no clinical features of active TB, and have a screening chest x-ray with no evidence of active TB may be enrolled if other entry criteria met. Such patients would not be required to undergo the protocol-specific TB testing for PPD, QuantiFERON®-TB Gold test, or T-SPOT®.TB test but must have a chest x-ray at screening (i.e., chest imaging performed within the past 6 months will not be accepted).
  • Have received any of the following medications:
  • Cyclophosphamide (or any other cytotoxic agent) within 4 weeks of screening.
  • Rituximab or any other B cell depleting therapies within 12 weeks of screening.
  • Have been treated with probenecid that cannot be discontinued for the duration of the study.
  • Have been exposed to a live vaccine within 12 weeks of randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination).
  • Note: All patients who have not previously received the herpes zoster vaccine by screening will be encouraged (per local guidelines) to do so prior to randomization; vaccination with live herpes zoster vaccine must occur >4 weeks prior to randomization and start of investigational product. Patients will not be randomized if they were exposed to a live herpes zoster vaccination within 4 weeks of planned randomization. Investigators should review the vaccination status of their patients and follow the local guidelines for vaccination of patients ≥18 years of age with nonlive vaccines intended to prevent infectious disease prior to entering patients into the study.
  • Are currently enrolled in or have discontinued within 4 weeks of screening from any other clinical trial involving an investigational product or nonapproved use of a drug or device or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population that, in the opinion of the investigator, pose an unacceptable risk for the patient's participation in the study. Patients who are receiving thyroxine as replacement therapy may participate in the study, provided stable therapy has been administered for ≥12 weeks and TSH is within the laboratory's reference range. Patients who have TSH marginally outside the laboratory's normal reference range and are receiving stable thyroxine replacement therapy may participate if the treating physician has documented that the thyroxine replacement therapy is adequate for the patient
  • Have any of the following specific abnormalities on screening laboratory tests from the central or local laboratory
  • ALT or AST >2 x upper limits of normal (ULN)
  • alkaline phosphatase (ALP) ≥2 x ULN
  • total bilirubin ≥1.5 x ULN
  • hemoglobin <10 g/dL (100.0 g/L)
  • total white blood cell count <3000 cells/μL (<3.00 x 103/μL or <3.00 billion/L)
  • neutropenia (absolute neutrophil count [ANC] <1500 cells/uL) (<1.50 x 103/uL or <1.50 billion/L)
  • lymphopenia (lymphocyte count <1000 cells/uL) (<1.00 x 103/μL or <1.00 bilion/L)
  • thrombocytopenia (platelets <100,000 cells/uL) (<100 x 103/μL or <100 billion/L)
  • eGFR <60 mL/min/1.73 m2 (Bedside Schwartz formula 2009) In the case of any of the aforementioned laboratory abnormalities, the tests may be repeated once during screening, and values resulting from repeat testing may be accepted for enrollment eligibility if they meet the eligibility criterion
  • Other Exclusions
  • Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden or confined to wheelchair
  • In the opinion of the investigator, are at an unacceptable risk for participating in the study
  • Have donated more than a single unit of blood within 4 weeks prior to screening or intend to donate blood during the course of the study
  • Have a history of intravenous drug abuse, other illicit drug abuse, or chronic alcohol abuse within the 2 years prior to screening or are concurrently using, or expected to use during the study, illicit drugs (including marijuana)
  • Note: Patients who are prescribed medical marijuana by a physician are not excluded from the study.
  • Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures
  • Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Barnes Jewish Hospital / Washington University in St. Louis

    St Louis, Missouri, 63110

Other trials in United States

About this study

Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need.

At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP.

This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.

Being tested
Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
Medical subject headings
Pemphigoid, Benign Mucous Membrane

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Baricitinib 2 MG [Olumiant]Drug

    Two tabs daily

  • MethotrexateDrug

    Target dose: 20mg weekly

  • AzathioprineDrug

    Target dose: 2mg/kg daily

  • MycophenolateDrug

    Target Dose: 1g twice daily

Study groups in NCT05263505
Study groupRoleWhat they receive
BaricitinibExperimental4mg daily
Receives: Drug: Baricitinib 2 MG [Olumiant]
AntiproliferativeActive comparatormethotrexate, azathioprine, or mycophenolate
Receives: Drug: Methotrexate; Drug: Azathioprine; Drug: Mycophenolate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment Response

    Treatment response of ocular inflammation based on conjunctival injection measured by ophthalmologic exam of the palpebral conjunctiva. Each eye is divided into quadrants and each quadrant is scored from 0 (white and quite) to 3 (severe). The score will be the sum of all 4 quadrants for a total score of 0-12 for each eye. A clinically meaningful response will be defined as a ≥30% reduction in the total score for both eyes.

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2022
  2. Study start21 Feb 2022
  3. Primary completion11 Sep 2023
  4. Study completion11 Sep 2023

Why it stopped: Sponsor

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
2 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05263505
Sponsor's protocol ID
202107009
Status last verified
Oct 2023
First submitted
16 Feb 2022
Last updated
7 Nov 2023
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Baricitinib 2 MG [Olumiant], Methotrexate and Azathioprine in people with Mucous Membrane Pemphigoid and Cicatrizing Conjunctivitis, run by Washington University School of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 38 inclusion and 62 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 7 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 Nov 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment Response (time frame: 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05263505.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in